Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Actinium Pharmaceuticals Inc (ATNM)

Actinium Pharmaceuticals Inc (ATNM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 42,723
  • Shares Outstanding, K 164,701
  • Annual Sales, $ 0 K
  • Annual Income, $ -23,650 K
  • 60-Month Beta 1.91
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.99
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.18
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/22/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.04
  • Number of Estimates 1
  • High Estimate -0.04
  • Low Estimate -0.04
  • Prior Year -0.06
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.20 +29.70%
on 11/19/19
0.31 -16.30%
on 12/03/19
-0.01 (-4.25%)
since 11/06/19
3-Month
0.19 +36.53%
on 10/11/19
0.41 -36.73%
on 10/25/19
+0.04 (+19.48%)
since 09/06/19
52-Week
0.19 +36.53%
on 10/11/19
0.71 -63.46%
on 02/21/19
-0.21 (-44.81%)
since 12/06/18

Most Recent Stories

More News
What Makes Actinium (ATNM) a New Buy Stock

Actinium (ATNM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ATNM : 0.26 (+6.31%)
Actinium Pharmaceuticals to Present at the 25th Annual BIO-Europe® 2019 International Partnering Conference

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") announced today that it will attend the 25th Annual BIO-Europe® International Partnering Conference being held November 11 - 13, 2019...

ATNM : 0.26 (+6.31%)
Actinium Announces Interim Results from Phase 1 Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML Accepted for Presentation at ASH 2019

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that interim results from a Phase 1 trial studying Actimab-A in combination with CLAG-M have been accepted for presentation...

ATNM : 0.26 (+6.31%)
Actinium Pharmaceuticals to Present New Clinical Findings from SIERRA Trial Supporting the Iomab-ACT Program for Targeted Lymphodepletion for CAR-T and Adoptive Cell Therapies at ASH 2019

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that new findings from its pivotal Phase 3 SIERRA trial for Iomab-B (Iodine-131 apamistamab) that support its Iomab-ACT...

ATNM : 0.26 (+6.31%)
Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enrollment

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced key interim findings from the pivotal Phase 3 SIERRA trial of Iomab-B, including feasibility and safety data, at 50% of...

ATNM : 0.26 (+6.31%)
Actinium to Announce Interim Results from Pivotal Phase 3 SIERRA Trial on Conference Call Scheduled for Monday, October 28th

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") announced today that it will a host a conference call and webcast to highlight interim results from the pivotal Phase 3 SIERRA trial for...

ATNM : 0.26 (+6.31%)
Actinium Announces Participation at the 2019 Cell & Gene Meeting on the Mesa

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that it will be attending the 2019 Cell & Gene Meeting on the Mesa being held October 2nd - October 4th in Carlsbad, CA....

ATNM : 0.26 (+6.31%)
Actinium Announces Iomab-B Poster Selected for Honorable Distinction Award at the 2019 Society of Hematologic Oncology Annual Meeting from Nearly Four Hundred Abstracts

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that a poster highlighting Iomab-B, its pivotal Phase 3 targeted conditioning candidate, was awarded Honorable Distinction...

ATNM : 0.26 (+6.31%)
Actinium Pharmaceuticals to Present at the Sachs 19th Annual Biotech in Europe Forum for Global Partnering & Investment

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that it will present at the Sachs 19th Annual Biotech in Europe Forum for Global Partnering & Investment. The forum is...

ATNM : 0.26 (+6.31%)
Actinium Pharmaceuticals to Present at the Rodman & Renshaw 21st Annual Global Investment Conference

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium"), today announced that it will present at the Rodman & Renshaw 21st Annual Global Investment Conference. The conference is being held at...

ATNM : 0.26 (+6.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade ATNM with:

Business Summary

Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company's principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition...

See More

Key Turning Points

2nd Resistance Point 0.28
1st Resistance Point 0.27
Last Price 0.26
1st Support Level 0.25
2nd Support Level 0.23

See More

52-Week High 0.71
Fibonacci 61.8% 0.51
Fibonacci 50% 0.45
Fibonacci 38.2% 0.39
Last Price 0.26
52-Week Low 0.19

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar